MAM
Cashify levels up its tech game as Raghvendra Singh takes the CTO helm
MUMBAI: When scale is the goal, the right code captain matters. Cashify has appointed Raghvendra Singh as its chief technology officer, effective January 1, 2026, signalling a sharpened focus on technology as the backbone of its next growth phase.
The elevation comes at a time when Cashify is gearing up for a strong year ahead, with the company projecting 30–35 per cent growth, expanding beyond smartphones into new device categories, and scaling its offline footprint to over 300 planned retail stores across India. The move reflects a deliberate bet on leadership continuity as the company accelerates its recommerce ambitions.
Raghvendra is no stranger to the organisation. Having spent more than a decade at Cashify, he most recently served as head of engineering and has previously held roles including senior vice president and vice president of engineering. Over the years, he has been closely involved in building the company’s consumer platforms and internal systems that power large-scale device buyback, pricing and verification.
In his new role, Raghvendra will oversee Cashify’s end-to-end technology strategy, spanning platform architecture, engineering, infrastructure and security. The mandate underlines the company’s belief that robust, scalable technology is central to reliability, trust and long-term competitiveness in the circular economy.
Commenting on the appointment, Cashify co-founder and CEO Mandeep Manocha said Raghvendra has been instrumental in building the proprietary platforms and data-led systems that enable device reuse at scale across India. As CTO, he will further strengthen the technology roadmap to drive efficiency, sustainability and trust across the entire device lifecycle.
Raghvendra said his focus as CTO would be on creating a resilient, future-ready technology foundation, with deeper integration of AI and data into platforms and decision-making systems. He added that strengthening reliability, security and execution speed would be key priorities as Cashify continues to scale.
With an internal leader stepping up at a critical moment, Cashify is making it clear that its next phase of growth will be powered as much by engineering depth as by ambition.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
